Gemcitabine induces programmed cell death and activates protein kinase C in BG-1 human ovarian cancer cells

被引:22
作者
Cartee, L [1 ]
Kucera, GL [1 ]
机构
[1] Wake Forest Univ, Ctr Comprehens Canc, Winston Salem, NC 27157 USA
关键词
gemcitabine; programmed cell death; protein kinase C; ovarian cancer;
D O I
10.1007/s002800050758
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: Cytosine arabinoside induces apoptosis and this cell death process is influenced by protein kinase C signaling events in leukemic cells. We present findings that extend these observations to include another deoxycytidine analog, gemcitabine, which is more potent in solid tumors. Methods and results: Gemcitabine induced programmed cell death in BG-1 human ovarian cancer cells based on biochemical and morphologic analyses. The DNA was fragmented in BG-1 cells exposed to gemcitabine (0.5 mu M, 1.0 mu M and 10 mu M) for 8 h, but gemcitabine treatment did not induce internucleosomal DNA degradation. Scanning and transmission electron microscopy of BG-1 cells showed morphologic changes associated with apoptosis in response to gemcitabine: membrane blebbing, the forma tion of apoptotic bodies and chromatin condensation. Thus, BG-1 cells undergo programmed cell death in response to gemcitabine treatment without internucleosomal DNA fragmentation. Furthermore, gemcitabine (10 mu M) activated protein kinase C in BG-1 cells and the phosphorylation of the endogenous protein kinase C substrate, myristoylated alanine-rich C kinase substrate, was increased following exposure of BG-1 cells to gemcitabine for up to 6 h. Clonogenicity studies with gemcitabine in combination with various protein kinase C-modulating agents demonstrated that gemcitabine cytotoxicity was influenced by protein kinase C signaling events in BG-1 cells. Short-term (1 h) exposure to TPA (1 or 10 nM) followed by gemcitabine (0.5 mu M for 4 h) did not alter the response to gemcitabine. However, a 24-h exposure to TPA followed by gemcitabine resulted in synergistic cytotoxicity, while coincubation of TPA with a PKC inhibitor (e.g. bisindolylmaleimide or calphostin-C) in this regimen abrogated the synergistic response. Conclusions: Based on our findings, it is plausible that gemcitabine therapy could be improved by modulating PKC signaling events linked to drug-induced apoptosis/cytotoxicity.
引用
收藏
页码:403 / 412
页数:10
相关论文
共 42 条
[1]  
BHALLA K, 1991, BLOOD, V78, P2674
[2]  
BHALLA K, 1992, BLOOD, V80, P2883
[3]  
Bhalla K, 1993, Leuk Lymphoma, V10 Suppl, P123, DOI 10.3109/10428199309149124
[4]  
Bouffard David Y., 1994, Proceedings of the American Association for Cancer Research Annual Meeting, V35, P317
[5]   THE INFLUENCE OF THE SCHEDULE AND THE DOSE OF GEMCITABINE ON THE ANTITUMOR EFFICACY IN EXPERIMENTAL HUMAN CANCER [J].
BOVEN, E ;
SCHIPPER, H ;
ERKELENS, CAM ;
HATTY, SA ;
PINEDO, HM .
BRITISH JOURNAL OF CANCER, 1993, 68 (01) :52-56
[6]  
CARBALLO E, 1995, LEUKEMIA, V9, P834
[7]  
CHEPENIK KP, 1988, J CRAN GENET DEV BIO, V8, P147
[9]   ENHANCED HEMATOPOIETIC ACTIVITY OF A HUMAN GRANULOCYTE MACROPHAGE COLONY-STIMULATING FACTOR INTERLEUKIN-3 FUSION PROTEIN [J].
CURTIS, BM ;
WILLIAMS, DE ;
BROXMEYER, HE ;
DUNN, J ;
FARRAH, T ;
JEFFERY, E ;
CLEVENGER, W ;
DEROOS, P ;
MARTIN, U ;
FRIEND, D ;
CRAIG, V ;
GAYLE, R ;
PRICE, V ;
COSMAN, D ;
MARCH, CJ ;
PARK, LS .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1991, 88 (13) :5809-5813
[10]  
DEVENTE J, 1995, CELL GROWTH DIFFER, V6, P371